Evaxion Biotech A/S Overview
Valuation check: EVAX's ROE is -91.13%, below the Healthcare sector average of 11.15%.
Get informed when a big investor buys or sells
+ Follow-91.13%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for EVAX is -91.13%. That is below the Healthcare sector average of 11.15%. Investors often review this figure alongside Evaxion Biotech A/S's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, EVAX currently prints -91.13% for ROE, while the sector average sits near 11.15%. That is roughly 917.0% below the sector mean. Large gaps often invite a closer look at Evaxion Biotech A/S's growth, margins, and balance sheet.
Return on Equity shows how effectively Evaxion Biotech A/S converts resources into returns. At -91.13%, EVAX may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting EVAX's ROE (-91.13%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Evaxion Biotech A/S's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
